Live

China, EU retaliate as Trump's massive tariffs kick in across the world. See the latest.

Frankfurt - Delayed Quote EUR

Bavarian Nordic A/S (BV3.F)

18.90

-0.10

(-0.53%)

As of 2:56:58 PM GMT+2. Market Open.

No Tool

Measure

UNDO

Redo

All

All

Favorites

Text

Statistics

Technicals

Fibonacci

Markings

Lines

Annotation

Arrow

Line

Horizontal

Vertical

Rectangle

Trend Line

Measurement Line

Average Line

Callout

Channel

Check

Continuous

Crossline

Elliott Wave

Ellipse

Doodle

Fib Projection

Fib Arc

Fib Fan

Fib Time Zone

Focus

Gann Fan

Gartley

Heart

Pitchfork

Quadrant Lines

Ray

Regression Line

Fib Retracement

Star

Speed Resistance Arc

Speed Resistance Line

Time Cycle

Tirone Levels

Volume Profile

Cross

Loading Chart for BV3.F

Resolutions of the Annual General Meeting 2025 of Bavarian Nordic A/S

Resolutions of the Annual General Meeting 2025 of Bavarian Nordic A/S

FDA approves Bavarian Nordic’s freeze-dried mpox and smallpox vaccine

FDA approves Bavarian Nordic’s freeze-dried mpox and smallpox vaccine

Bavarian Nordic Receives U.S. FDA Approval of Freeze-Dried Smallpox and Mpox Vaccine

Bavarian Nordic Receives U.S. FDA Approval of Freeze-Dried Smallpox and Mpox Vaccine

Bavarian Nordic A/S – Notice Convening Annual General Meeting

Bavarian Nordic A/S – Notice Convening Annual General Meeting

Bavarian Nordic Announces Acceptance of Marketing Authorization Application for Chikungunya Vaccine in the UK for Persons Aged 12 and Older

Bavarian Nordic Announces Acceptance of Marketing Authorization Application for Chikungunya Vaccine in the UK for Persons Aged 12 and Older

Bavarian Nordic AS (BVNKF) Q4 2024 Earnings Call Highlights: Strong Vaccine Growth and ...

Bavarian Nordic AS (BVNKF) Q4 2024 Earnings Call Highlights: Strong Vaccine Growth and ...

Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such

Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such

Bavarian Nordic Publishes Annual Report 2024

Bavarian Nordic Publishes Annual Report 2024

EC approves Bavarian Nordic’s chikungunya vaccine marketing

EC approves Bavarian Nordic’s chikungunya vaccine marketing

Bavarian Nordic Receives Marketing Authorization in Europe for Chikungunya Vaccine for Persons Aged 12 and Older

Bavarian Nordic Receives Marketing Authorization in Europe for Chikungunya Vaccine for Persons Aged 12 and Older

Bavarian Nordic Partners with Biological E Limited to Expand Global Access to Chikungunya Vaccine

Bavarian Nordic Partners with Biological E Limited to Expand Global Access to Chikungunya Vaccine

BNTX.VI BioNTech SE

77.05

-4.88%

NVV1.F Novavax, Inc.

5.71

+1.76%

IDIA.SW Idorsia Ltd

1.0100

+4.66%

VLA.PA Valneva SE

2.8200

-5.50%

EVFM Evofem Biosciences, Inc.

0.0086

-1.15%

CVAC CureVac N.V.

2.7500

+1.10%

REGN Regeneron Pharmaceuticals, Inc.

535.84

-3.77%